Application No. 10/694,207 Reply to Office Action of September 20, 2006 Page 6 of 8

Amendments to the Drawings:

Figures 1-26 have been amended to include the relevant sequence identifiers were appropriate. No new matter has been added.

Attachment: Replacement sheet

Annotated Marked-up Drawings

REMARKS

Amendments to the Specification

The specification has been amended to comply with the requirements of 37 C.F.R. 1.821-1.825. Specifically, sequence identifiers have been added to the Figures and to the specification at pages 7-9 and 24 to accompany the sequence disclosures that are encompassed by the definitions for nucleotide sequences as set forth in 37 C.F.R. 1.821(a)(1). Although these sequences were not identified by a SEQ ID NO in the specification, they were part of the Sequence Listing filed with the United States Patent and Trademark Office on July 19, 2004. Therefore, a substitute computer readable form (CRF) copy and a substitute paper copy of the "Sequence Listing" are not required. No new matter has been added by this amendment.

Rejection For Failure To Comply With 37 C.F.R. §§ 1.821-1.825

The application has been rejected for failing to comply with the requirements of 37 C.F.R. § 1.821. Specifically, the Office Action states that the application references sequences by the identifier Oligo(s) rather than the proper identifier SEQ ID NO (citing page 30, line 5 as an example).

Applicants respectfully disagree. Nucleotide and/or amino acid sequences as used in §§ 1.821 through 1.825 are interpreted to mean an unbranched sequence of four or more amino acids or an unbranched sequence of ten or more nucleotides. 37 C.F.R. § 1.821(a)(1) states that nucleotides are intended to embrace only those nucleotides that can be represented using the symbols set forth in WIPO Standard ST.25 (1998), and (a)(2) states that Amino acids are those L-amino acids commonly found in naturally occurring proteins and are listed in WIPO Standard ST.25 (1998). Since the disclosure in the application, for example, at pages 29 and 30, do not meet these definitions, the application complies with the Sequence Listing requirements. Applicants are allowed to be their own lexicographers and can give whatever name they choose to the disclosed oligonucleotides. Sequence identifiers are only required where the sequence is disclosed. Reconsideration and withdrawal of the rejection are respectfully requested.

Application No. 10/694,207 Reply to Office Action of September 20, 2006 Page 8 of 8

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned.

Respectfully submitted,

Dated: October 23 2006

Keown & Associates 500 West Cummings Park Suite 1200

Woburn, MA 01801

Telephone: 781/938-1805 Facsimile: 781/938-4777 Joseph C. Zucchero Registration No. 55,762



Oligo No.

Sequence & Modification

SEQ ID NO.: 10

SEQ ID NO.: 14

SEQ ID NO.: 15

SEQ ID NO.: 22

23

SEQ ID NO.: 23

SEQ ID NO.: 8

SEQ ID NO.: 9

SEQ ID NO.: 11

SEQ ID NO.: 12

SEQ ID NO.: 13

SEQ ID NO.: 16

SEQ ID NO.: 17

SEQ ID NO.: 18

SEQ ID NO.: 19

SEQ ID NO.: 20

SEQ ID NO.: 21

5'-CCTACTAG<u>CG</u>TTCTCATC-3' (133-1)

5'-CCTACTAGCXTTCTCATC-3' (139-2)

5'-CCTACT**X**GCGTTCTCATC-3' (139-3) 5'-CCTACTAXCGTTCTCATC-3' (133-2)

5'-CCTACXAGCGTTCTCATC-3' (133-3)

5'-CCTAXTAGCGTTCTCATC-3' (139-4)

5'-CCTXCTAG<u>CC</u>TTCTCATC-3' (145-10a) 5'-CCTXCTAGCGTTCTCATC-3' (133-4)

5'-CCTACTAGCGXTCTCATC-3' (133-5) 5'-CCTACTAGCGTXCTCATC-3' (139-7)

1,2'-Dideoxyribose


5'-CCTACTAGCGTTCXCATC-3' (139-8) 5'-CCTACTAGCGTTXTCATC-3' (133-6)

5'-CCTXXTAGCGTTCTCATC-3' (133-12)

5'-XXTACTAGCGTTCTCATC-3' (139-6) 5'-CCTACTAGCGTTCXXATC-3' (139-9)

5'-CCTXCTXGCGTTCTCATC-3' (145-10b)

FIG. 1A



	_	Ų
•	2	2
	,	_
	١	ર
	?	∑,
7	>	₹
(•	J

Sequence & Modification

SEQ ID NO.: 14 SEQ ID NO.: 15 SEQ ID NO.: 12 SEQ ID NO.: 13 SEQ ID NO.: 10 SEQ ID NO.: 11 SEQ ID NO.: 9 SEQ ID NO.: 8

SEQ ID NO.: 16 **SEQ ID NO.: 17**

SEQ ID NO.: 18

SEQ ID NO.: 19

SEQ ID NO.: 20

SEQ ID NO.: 23 SEQ ID NO.: 22 **SEQ ID NO.: 21**

5'-CCTACTAG<u>CG</u>TTCTCATC-3' (133-1)

5-CCTACTAGCXTTCTCATC-3' (139-2)

5'-CCTACTAXCGTTCTCATC-3' (133-2)

5'-CCTACT**X**GCGTTCTCATC-3' (139-3)

5'-CCTACXAGCGTTCTCATC-3' (133-3) 5'-CCTAXTAGCGTTCTCATC-3' (139-4)

5'-CCTXCTAG<u>CC</u>TTCTCATC-3' (145-10a) 5'-CCTXCTAGCGTTCTCATC-3' (133-4)


5'-CCTACTAGCGXTCTCATC-3' (133-5)

1',2'-Dideoxyribose

5'-CCTACTAGCGTXCTCATC-3' (139-7) 5'-CCTACTAGCGTTXTCATC-3' (133-6) 5'-CCTACTAGCGTTCXCATC-3' (139-8)

5'-CCTXXTAGCGTTCTCATC-3' (133-12) 5'-XXTACTAGCGTTCTCATC-3' (139-6)

5'-CCTXCTXGCGTTCTCATC-3' (145-10b) 5'-CCTACTAGCGTTCXXATC-3' (139-9)



Modification
Sequence 8
Oligo No.

SEQ ID NO: 1		5'-CTATCTGACGTTCTCTGT-3' (131-1)
SEQ ID NO.: 105 2	6 1	5'-CTATCTGAXGTTCTCTGT-3' (131-13)
SEQ ID NO.: 106 3	•	5'-CTATCTGXCGTTCTCTGT-3' (131-2)
SEQ ID NO.: 107 4		5'-CTATCXGACGTTCTCTGT-3' (131-3)
SEQ ID NO.: 108 5		5'-CTAXCTGACGTTCTCTGT-3' (131-4)
SEQ ID NO.: 109 6	' 0	5'-CTATCTGACGXTCTCTGT-3' (131-5)
SEQ ID NO.: 110 7		5'-CTATCTGACGTTXTCTGT-3' (131-6)

$$X = 3'$$

$$0 = 0$$

$$0 = 0$$

$$0 = 0$$

$$0 = 0$$
1',2'-Dideoxyribose

FIG. 3A




FIG. 3B

SEQ ID NO.: 105 SEQ ID NO.: 106

SEQ ID NO.: 1

SEQ ID NO.: 108 SEQ ID NO.: 109 SEQ ID NO.: 110

SEQ ID NO.: 107

Oligo No.

Sequence & Modification

5'-CTATCTGAXGTTCTCTGT-3' (131-13) 5'-CTATCTGA<u>CG</u>TTCTCTGT-3' (131-1)

5'-CTATCXGACGTTCTCTGT-3' (131-3) 5'-CTAXCTGACGTTCTCTGT-3' (131-4) 5'-CTATCTGXCGTTCTCTGT-3' (131-2)

5'-CTATCTGACGXTCTCTGT-3' (131-5) 5'-CTATCTGACGTTXTCTGT-3' (131-6)

1',2'-Dideoxyribose





FIG. 4B

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND MODIFICATION OF LINKAGES

0	Oligo No.	Sequence & Modification
SEQ ID NO.: 8	133-1	5'-CCTACTAGCGTTCTCATC-3'
SEQ ID NO.: 24	141-2	5'-CCTACTAGCXTTCTCATC-3'
SEQ ID NO.: 25	141-3	5'-CCTACTXGCGTTCTCATC-3'
SEQ ID NO.: 26	141-4	5'-CCTAXTAGCGTTCTCATC-3'
SEQ ID NO.: 27	141-5	5'-CCTXXTAGCGTTCTCATC-3'
SEQ ID NO.: 28	141-6	5- XX TACTAGCGTTCTCATC-3'
SEQ ID NO.: 29	141-7	5'-CCTACTAGCGTXCTCATC-3'
SEQ ID NO.: 30	141-8	5'-CCTACTAGCGTTCXCATC-3' 0=,P-0
SEQ ID NO.: 31	141-9	5'-CCTACTAGCGTTCXXATC-3' 5'-CCTACTAGCGTTCXXATC-3'
SEQ ID NO.: 1	131-1	5'-CTATCTGACGTTCTCTGT-3'
SEQ ID NO.: 32	137-2	5'-CTATCTGXCGTTCTCTGT-3'
SEQ ID NO.: 33	137-3	5'-CTATCXGACGTTCTCTGT-3'
SEQ ID NO.: 34	137-4	5'-CTAXCTGACGTTCTCTGT-3'
OL & 10 150:		

FIG. 5A




OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND MODIFICATION OF LINKAGES


0	Oligo No.	Sequence & Modification
SEQ ID NO.: 8	133-1	5'-CCTACTAGCGTTCTCATC-3'
SEQ ID NO.: 24	141-2	5'-CCTACTAGCXTTCTCATC-3'
SEQ ID NO.: 25	141-3	5'-CCTACTXGCGTTCTCATC-3' 5'-O
SEO ID NO : 26	141-4	5'-CCTAXTAGCGTTCTCATC-3'
SEO ID NO · 27	141-5	5'-CCTXXTAGCGTTCTCATC-3'
SEO ID NO: 28	141-6	5'-XXTACTAGCGTTCTCATC-3'
SEO ID NO: 29	141-7	5'-CCTACTAGCGTXCTCATC-3'
SEO ID NO : 30	141-8	5'-CCTACTAGCGTTCXCATC-3'
SEQ ID NO.: 31	141-9	5'-CCTACTAGCGTTCXXATC-3'
SEC ID NO - 1	131-1	5'-CTATCTGACGTTCTCTGT-3'
SEQ ID NO.: 32	137-2	5'-CTATCTGXCGTTCTCTGT-3'
SEQ ID NO.: 33	137-3	5'-CTATCXGACGTTCTCTGT-3'
SEQ ID NO.: 34	137-4	5'-CTAXCTGACGTTCTCTGT-3'

FIG. 6A

12/53



Sequence & Modification	5'-CTATCTGA <u>CG</u> TTCTCTGT-3' (131-1)	5'-CTAXCTGACGTTCTCTGT-3' (153-1)	5'-CTATCTGACGTTCXCTGT-3' (153-2)	5'-CTAYCTGACGTTCTCTGT-3' (153-3)	5'-CTATCTGACGTTCYCTGT-3' (153-4)	5'-CCTACTAGCGTTCTCATC-3' (133-1)	5'-CCTXCTAGCGTTCTCATC-3' (155-1)	5'-CCTACTAGCGTTCXCATC-3' (155-2)	5'-CCTYCTAGCGTTCTCATC-3' (155-3)	5'-CCTACTAGCGTTCYCATC-3' (155-4)	
Oligo No.	_	7	က	4	2	9	2	&	6	10	
'iO	SEQ ID NO: 1	SEQ ID NO.: 35	SEQ ID NO.: 36	SEQ ID NO.: 37	SEQ ID NO.: 38	SEQ ID NO.: 8	SEQ ID NO.: 39	SEQ ID NO.: 40	SEQ ID NO.: 41	SEQ ID NO.: 42	




lO	Oligo No.	Sequence & Modification
SEQ ID NO.: 1	_	5'-CTATCTGA <u>CG</u> TTCTCTGT-3' (131-1)
SEQ ID NO.: 35	7	5'-CTAXCTGACGTTCTCTGT-3' (153-1)
SEQ ID NO.: 36	က	5'-CTATCTGACGTTCXCTGT-3' (153-2)
SEQ ID NO.: 37	4	5'-CTAYCTGACGTTCTCTGT-3' (153-3)
SEQ ID NO.: 38	2	5'-CTATCTGACGTTCYCTGT-3' (153-4)
SEQ ID NO.: 8	9	5'-CCTACTAGCGTTCTCATC-3' (133-1)
SEQ ID NO.: 39	7	5'-CCTXCTAGCGTTCTCATC-3' (155-1)
SEQ ID NO.: 40	œ	5'-CCTACTAGCGTTCXCATC-3' (155-2)
SEQ ID NO.: 41	6	5'-CCTYCTAGCGTTCTCATC-3' (155-3)
SEQ ID NO.: 42	10	5'-CCTACTAGCGTTCYCATC-3' (155-4)

$$X = x_0 \\ 0 = \frac{1}{2} \\ \text{Spacer9}$$

$$Y = x^0 \\ 0 = \frac{1}{2} \\ \text{Spacer18}$$

$$FIG. 8A$$

16/53



Oligo No.

Sequence & Modification

SEQ ID NO.: 1

SEQ ID NO.: 43 2


SEQ ID NO.: 45 4

SEQ ID NO.: 46 5

5'-CTATCTGACGTTCTCTGT-3' (131-1)
5'-CTATCTGXCGTTCTCTGT-3' (157-1)
5'-CTATCTXACGTTCTCTGT-3' (157-2)
5'-CTAXCTGACGTTCTCTGT-3' (157-3)

5'-CTAXCTGACGTTCTCTGT-3' (157-3) 5'-CTATCTGACGTXCTCTGT-3' (157-4) 5'-CTATCTGACGTTCXCTGT-3' (157-5) $X = X = H_{2N}$ Amino-Linker

FIG. 9A



Oligo No.

Sequence & Modification

SEQ ID NO.: 1

SEQ ID NO.: 43

SEQ ID NO.: 45 SEQ ID NO.: 44

SEQ ID NO.: 46

SEQ ID NO.: 47

5'-CTATCTGACGTTCXCTGT-3' (157-5) 5'-CTATCTGACGTXCTCTGT-3' (157-4) 5'-CTATCTGACGTTCTCTGT-3' (131-1) 5'-CTATCTGXCGTTCTCTGT-3' (157-1) 5'-CTAXCTGACGTTCTCTGT-3' (157-3) 5'-CTATCTXACGTTCTCTGT-3' (157-2)

Amino-Linker

FIG. 10A





FIG. 10B

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND MODIFICATION OF LINKAGES

Oligo No.	Sequence & Modification	
SEQ ID NO.: 1 131-1	5'-CTATCTGACGTTCTCTGT-3'	
SEQ ID NO.: 48 159-1	5'-CTATCTGACXTTCTCTGT-3'	0-
SEQ ID NO.: 49 159-2	5'-CTATCTGAXGTTCTCTGT-3'	X = 5' 0 \ 0 \ '0 \ '0 \ '0 \ '0 \ '0 \ '0
SEQ ID NO.: 50 159-3	5'-CTATXTGACGTTCTCTGT-3'	
SEQ ID NO.: 51 159-4	5'-CTATCTGACGTTCTXTGT-3'	0-4=0
SEQ ID NO.: 8 133-1	5'-CCTACTAGCGTTCTCATC-3'	/
SEQ ID NO.: 52 161-1	5'-CCTACTAGCXTTCTCATC-3'	50
SEQ ID NO.: 53 161-2	5'-CCTACTAGXGTTCTCATC-3'	3'-Deoxynucleoside
SEQ ID NO.: 54 161-3	5'-CCTACTAXCGTTCTCATC-3'	
SEQ ID NO.: 55 161-4	5'-CCTAXTAGCGTTCTCATC-3'	
SEQ ID NO.: 56 161-5	5'-CCTACTAGCGTTCTXATC-3'	

21/53

FIG. 11A




OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND MODIFICATION OF LINKAGES

Oligo No.	Sequence & Modification	
SEQ ID NO.: 1 131-1	5'-CTATCTGACGTTCTCTGT-3'	
SEQ ID NO.: 48 159-1	5'-CTATCTGACXTTCTCTGT-3'	0-
SEQ ID NO.: 49 159-2	5'-CTATCTGAXGTTCTCTGT-3'	$X = 5' \left(0 \right)^{B}$
SEQ ID NO.: 50 159-3	5'-CTATXTGACGTTCTCTGT-3'	
SEQ ID NO.: 51 159-4	5'-CTATCTGACGTTCTXTGT-3'	O-4::0
	•	S (5, 0, 8
SEQ ID NO.: 8 133-1	5'-CCTACTAGCGTTCTCATC-3'	
SEQ ID NO.: 52 161-1	5'-CCTACTAGCXTTCTCATC-3'	ر د د
SEQ ID NO.: 53 161-2	5'-CCTACTAGXGTTCTCATC-3'	3'-Deoxynucleoside
SEQ ID NO.: 54 161-3	5'-CCTACTAXCGTTCTCATC-3'	
SEQ ID NO.: 55 161-4	5'-CCTAXTAGCGTTCTCATC-3'	
SEQ ID NO.: 56 161-5	5'-CCTACTAGCGTTCTXATC-3'	

23/53

FIG. 12A

24/53



25/53


	١
(AGES	
ŽIJ.	
ION OF LI	
FICAT	
MODIFICATION	
IIOATES AND MOI	
ATES	September 1
OROTHIO,	
500	
HOSPHOI	
OLIGODEOXYNUCLEOTIDE PHO	
LEOT	
YNUC	
EOX	
JGOL.	
ರ	

Olig	Oligo No.	Sequence & Modification
SEQ ID NO.: 1	131-1	5'-CTATCTGACGTTCTCTGT-3'
SEQ ID NO.: 57	167-1	5'-CTATCTGXCGTTCTCTGT-3'
SEQ ID NO:: 58	167-2	5'-CTATCTXACGTTCTCTGT-3'
SEQ ID NO.: 59	167-3	5'-CTATCXGACGTTCTCTGT-3'
SEQ ID NO.: 60	167-4	5'-CTATXTGACGTTCTCTGT-3'
SEQ ID NO.: 61	167-5	5'-CTAXCTGACGTTCTCTGT-3'
SEQ ID NO.: 62	167-6	5'-CTXXCTGACGTTCTCTGT-3'
SEQ ID NO.: 63	167-7	5'-CTATCTGACGXTCTCTGT-3'
SEQ ID NO.: 64	167-8	5'-CTATCTGACGTXCTCTGT-3'
SEQ ID NO.: 65	167-9	5'-CTATCTGACGTTXTCTGT-3'
SEQ ID NO.: 66	167-10	5'-CTATCTGACGTTCXCTGT-3'
SEQ ID NO.: 67	16711	5'-CTATCTGACGTTCTXTGT-3'
SEQ ID NO.: 68 167-12	167-12	5'-CTATCTGACGTTCTXXGT-3'

$X = 5' \begin{cases} 0 \\ 3' \end{cases}$ $H_3C' \begin{cases} 0 \\ 0 \\ 0 \end{cases}$ Methyl-phosphonate

FIG. 13A





Methyl-phosphonate

S
띥
Š
Ž
_
6
Ž
9
Ä
유
岩
0
2
DE PHOSPHOROTHIOATES AND MODIFICATION OF LINKAC
¥
S
A
Q
王
Ö
9
픘
Š
오
Ω.
Ж
Ħ
0
兴
\preceq
\leq
X
DEOXYNUC
2
097
\exists

Oligo No.	Sequence & Modification
SEQ ID NO.: 1 131-1	s'-CTATCTGACGTTCTCTGT-3'
SEQ ID NO.: 57 167-1	5'-CTATCTGXCGTTCTCTGT-3'
SEQ ID NO.: 58 167-2	5'-CTATCTXACGTTCTCTGT-3'
SEO ID NO - 59 167-3	5'-CTATCXGACGTTCTCTGT-3'

SEQ ID NO.: 61 167-5

SEQ ID NO.: 60 167-4

SEQ ID NO.: 62 167-6

SEQ ID NO.: 63 167-7

SEQ ID NO.: 66 167-10


SEQ ID NO.: 64 167-8

SEQ ID NO.: 65 167-9

SEQ ID NO.: 67 16711

SEQ ID NO.: 68 167-12

28/53



AGES	
: LINK	
ON OF	
DIFICAT	
$\stackrel{>}{\geq}$	
TES AND I	
ð	
JROTHI	
IOSPHC	
무	
LEOTIDI	
NUN	
DEOXY	
OLIGO	

Oligo No.	Oligo No. Sequence & Modification		
50 113-1	5'-TCCATGACGTTCCTGATGC-3'	0-	
SEC ID NO. 69		8, C	-
SEQ ID NO.: 70 23-1	5'-TCCATGXCGTTCCTGATGC-3'		29/5
SEQ ID NO.: 71 23-3	5'-TCCAXGACGTTCCTGATGC-3'	o or	<u>3</u>
SEQ ID NO.: 72 29-2	5'-TYYATGACGGTCCTGATGC-3'	0=P-0 S *	

FIG. 15A

 $R_X = 2$ '-O-Methylribonucleoside Ry = 2'-O-Methoxyethoxyribonucleoside




FIG. 15B

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND MODIFICATION OF LINKAGES

on
ficatio
ð
Mo
প্ত
CG
equence
Пb
Se
6
<
igo
\approx

SEQ ID NO.: 69 113-1	5'-TCCATGACGTTCCTGATGC-3'
SEQ ID NO.: 70 23-1	5'-TCCATGXCGTTCCTGATGC-3'
SEQ ID NO.: 71 23-3	5'-TCCAXGACGTTCCTGATGC-3'
SEQ ID NO.: 72 29-2	5'-TYYATGACGGTCCTGATGC-3'

3' OR 3' OR O=P-O S, 1

31/53

 $R_{x} = 2$ '-O-Methylribonucleoside Ry = 2'-O-Methoxyethoxyribonucleoside

FIG. 16A





FIG. 16B

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND MODIFICATION OF LINKAGES

Oligo No.	Sequence & Modification
SEQ ID NO.: 73 1	5'GAGAACGCTCGACCTT-3'
SEQ ID NO.: 74 2	5'GAGAACGCTCGACCTT-3'5'-GAGAACGCTCGACCTT-3'
SEQ ID NO.: 75 3	3-TTCCAGCTCGCAAGAG-55'-GAGAACGCTCGACCTT-3'
SEQ ID NO.: 76 4	5'-GAGAACGCTCGACCTT-3' 3'-TTCCAGCTCGCAAGAG-5'
SEQ ID NO.: 77 5	5'-T C T C C C G C G C C A T-3'
SEQ ID NO.: 78 6	5'-T C C C A G C G T G C G C C A T-3' 5'-T C C C A G C G T G C G C C A T-3'
SEQ ID NO.: 79 7	3-TACCGCGTGCGACCCT-5' 5'TCCCAGCGTGCGCCAT-3'
SEQ ID NO.: 80 8	5'TCCCAGCGTGCGCCAT-3' 3'-TACCGCGTGCGACCCT-5'

FIG. 17B



Proliferation Index

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND MODIFICATION OF LINKAGES

	The second secon	The second secon
Oligo No.	Sequence & Modification	
SEQ ID NO.: 1 131-1	5'-CTATCTGACGTTCTCTGT-3'	
SEQ ID NO.: 81 175-1	5'-CTATXTGACGTTCTCTGT-3'	' , O-
SEQ ID NO.: 82 175-2	5'-CTATCTGACGTTCXCTGT-3'	$X = \frac{B}{A}$
SEQ ID NO.: 83 175-3	5'-CTAXXTGACGTTCTCTGT-3'	
SEQ ID NO.: 84 175-4	5'-CTATCTGACGTTCXXTGT-3'	0-4-0
SEQ ID NO.: 85 175-5	5'-CTATCTGAXXTTCTCTGT-3'	SO SO S
SEQ ID NO.: 86 175-6	5'-CTATCTXACGTTCTCTGT-3'	β -L-Deoxynucleoside 3'
SEQ ID NO.: 87 175-7	5'-CTATCTGACGTXCTCTGT-3'	, ,
SEQ ID NO.: 88 175-9	5'-CTATCTGACGTTCTCTGT-3' (all-β-L-DNA/PS)	L-DNA/PS)




FIG. 18B

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND MODIFICATION OF LINKAGES

Oligo No. Sequence & Modification

5'-CTATCTGACGTTCTCTGT-3'
5'-CTATXTGACGTTCTCTGT-3'

5'-CTATCTGACGTTCTXTGT-3'

SEQ ID NO.: 90 173-2

SEQ ID NO.: 1 131-1

SEQ ID NO.: 89 173-1

3. 19A

2'-O-Propargyl-ribonucleoside




FIG. 19B

40/53

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND MODIFICATION OF LINKAGES

0	Oligo No.	Sequence & Modification
SEQ ID NO.: 8	133-1	S'-CCTACTAGCGTTCTCATC-3'
SEQ ID NO.: 91	143-1	5'-CCTXXTAGCGTTCTCATC-3'
SEQ ID NO.: 92	143-2	5'-CCTYYTAGCGTTCTCATC-3'
SEQ ID NO.: 93	143-3	5'-CCTZZTAGCGTTCTCATC-3'
SEQ ID NO.: 94	143-4	5'-CCTXXTAGCGTVCTCATC-3'
SEQ ID NO.: 95	143-5	5'-CCTACTAGGCTTCTCATC-3'

FIG. 20A

X =1',2'-Dideoxyribose Y = C3-Linker Z = 3'-OMe V = 2'-OMe






FIG. 20B

42/53 OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND MODIFICATION OF LINKAGES

	Oligo No.	Sequence & Modification
SEQ ID NO.: SEQ ID NO.: SEQ ID NO.: SEQ ID NO.: SEQ ID NO.: SEQ ID NO.:	96 2 97 3 98 4 99 5	5'-CTATCTGACGTTCTCTGT-3' (131-1) 5'-CTATCTGACG*TTCTCTGT-3' (E 633L) 5'-CTATCTGAG*CTTCTCTGT-3' (E 636) 5'-TCTCCCAGCGTGCGCCAT-3' 5'-TCTCCCAGCG*TGCG*CCAT-3' (E 603) 5'-CTATXTGACG*TTCTCTGT-3' (E 639L) FIG. 21A
	NH	0 s





OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND SITE OF MODIFICATION

Oligo No.

Sequence & Modification

SEQ ID NO.: 1 SEQ ID NO.: 101

SEQ ID NO.: 102

5'-CTATCTGA<u>CG</u>TTCTCTGT-3' (131-1)
5'-CTATCTGA<u>CG*</u>TTCTCTGT-3' (E 682)
5'-CTATCTGA<u>G*C</u>TTCTCTGT-3' (E 683)

FIG. 22A




FIG. 22B

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND SITE OF MODIFICATION

Oligo No. Sequence & Modification

SEQ ID NO.: 2 5'-CTATCTGACGTTCTCTGT-3'
SEQ ID NO.: 3 5'-CTATCTGAC*TTCTCTGT-3'
SEQ ID NO.: 4 5'-CTATCTGACC*TTCTCTGT-3'
SEQ ID NO.: 5 5'-CTATCTGACC*TTCTCTGT-3'
SEQ ID NO.: 5 5'-CTATCTGACC**TTCTCTGT-3'

FIG. 23A

46/53




FIG. 23B


OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND SITE OF MODIFICATION

Oligo No. Sequence & Modification

SEQ ID NO.: 1 5'-CTATCTGACGTTCTCTGT-3'
SEQ ID NO.: 2 5'-CTATCTGAC*GTTCTCTGT-3'
SEQ ID NO.: 3 5'-CTATCTGACC*TTCTCTGT-3'
SEQ ID NO.: 4 5'-CTATCTGAC*GTTCTCTGT-3'
SEQ ID NO.: 5 5'-CTATCTGAC**TTCTCTGT-3'

 NH_{2} NH_{2} NH_{2} NH_{3} NH_{4} NH_{2} NH_{2} NH_{3} NH_{4} NH_{2} NH_{3} NH_{4} NH_{2} NH_{3} NH_{4} NH_{2} NH_{3} NH_{4} NH_{4} N

FIG. 24A



C* = Ara-C

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND SITE OF MODIFICATION

:47)

sequence & Modificatio

 	<u>۲</u>	
S'-CTATCTGA <u>CG</u> TTCTCTGT-3'	5'-CTATCTGA <u>C*G</u> TTCTCTGT-3'	5'-CTATCTGACC*TTCTCTGT-3'
	7 .	က
SEQ ID NO.: 1	SEQ ID NO.: 111	SEQ ID NO.: 112

FIG. 25A




FIG. 25B

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES AND SITE OF MODIFICATION

Oligo No. Sequence & Modification


C* = 4-Thiouracil S'-CTATCTGAC*GTTCTCTGT-3' (E 647) S'-CTATXTGAC*GTTCTCTGT-3' (E 653) 5'-CTATCTGACGTTCTCTGT-3' (131-1) SEQ ID NO.: SEQ ID NO.: SEQ ID NO.:

51/53

FIG. 26A

X = 1,2-Dideoxyribose

52/53



$$\begin{array}{c|c}
\underline{53/53} \\
NH_{2} \\
\hline
0 \\
0 \\
\hline
S \\
\hline
FIG. 27
\end{array}$$